SG11201709593VA - CRYSTAL OF (6S,9aS)-N-BENZYL-6-[(4-HYDROXYPHENYL)METHYL]- 4,7-DIOXO-8-({6-[3-(PIPERAZIN-1-YL)AZETIDIN-1-YL]PYRIDIN- 2-YL}METHYL)-2-(PROP-2-EN-1-YL)-OCTAHYDRO-1H-PYRAZINO[2,1-c][1,2,4]TRIAZINE-1-CARBOXAMIDE COMPOUND - Google Patents
CRYSTAL OF (6S,9aS)-N-BENZYL-6-[(4-HYDROXYPHENYL)METHYL]- 4,7-DIOXO-8-({6-[3-(PIPERAZIN-1-YL)AZETIDIN-1-YL]PYRIDIN- 2-YL}METHYL)-2-(PROP-2-EN-1-YL)-OCTAHYDRO-1H-PYRAZINO[2,1-c][1,2,4]TRIAZINE-1-CARBOXAMIDE COMPOUNDInfo
- Publication number
- SG11201709593VA SG11201709593VA SG11201709593VA SG11201709593VA SG11201709593VA SG 11201709593V A SG11201709593V A SG 11201709593VA SG 11201709593V A SG11201709593V A SG 11201709593VA SG 11201709593V A SG11201709593V A SG 11201709593VA SG 11201709593V A SG11201709593V A SG 11201709593VA
- Authority
- SG
- Singapore
- Prior art keywords
- methyl
- pyrazino
- azetidin
- octahydro
- piperazin
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Peptides Or Proteins (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562183577P | 2015-06-23 | 2015-06-23 | |
| PCT/JP2016/068381 WO2016208576A1 (ja) | 2015-06-23 | 2016-06-21 | （６Ｓ，９ａＳ）－Ｎ－ベンジル－６－［（４－ヒドロキシフェニル）メチル］－４，７－ジオキソ－８－（｛６－［３－（ピペラジン－１－イル）アゼチジン－１－イル］ピリジン－２－イル｝メチル）－２－（プロプ－２－エン－１－イル）－オクタヒドロ－１Ｈ－ピラジノ［２，１－ｃ］［１，２，４］トリアジン－１－カルボキサミド化合物の結晶 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201709593VA true SG11201709593VA (en) | 2017-12-28 |
Family
ID=57586245
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201709593VA SG11201709593VA (en) | 2015-06-23 | 2016-06-21 | CRYSTAL OF (6S,9aS)-N-BENZYL-6-[(4-HYDROXYPHENYL)METHYL]- 4,7-DIOXO-8-({6-[3-(PIPERAZIN-1-YL)AZETIDIN-1-YL]PYRIDIN- 2-YL}METHYL)-2-(PROP-2-EN-1-YL)-OCTAHYDRO-1H-PYRAZINO[2,1-c][1,2,4]TRIAZINE-1-CARBOXAMIDE COMPOUND |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US10259817B2 (zh) |
| EP (1) | EP3315499B1 (zh) |
| JP (1) | JP6126319B1 (zh) |
| KR (1) | KR102559211B1 (zh) |
| CN (1) | CN107614504B (zh) |
| AU (1) | AU2016284383B2 (zh) |
| CA (1) | CA2986999C (zh) |
| ES (1) | ES2870013T3 (zh) |
| IL (1) | IL255901B (zh) |
| MX (1) | MX2017015257A (zh) |
| RU (1) | RU2723551C2 (zh) |
| SG (1) | SG11201709593VA (zh) |
| WO (1) | WO2016208576A1 (zh) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3444363B1 (en) | 2011-06-03 | 2020-11-25 | Eisai R&D Management Co., Ltd. | Biomarkers for prediciting and assessing responsiveness of thyroid and kidney cancer subjects to lenvatinib compounds |
| BR112017002827B1 (pt) | 2014-08-28 | 2023-04-18 | Eisai R&D Management Co., Ltd | Derivado de quinolina altamente puro e método para produção do mesmo |
| MX2017010474A (es) | 2015-02-25 | 2017-11-28 | Eisai R&D Man Co Ltd | Metodo para suprimir el amargor de un derivado de quinoleina. |
| KR20240064733A (ko) | 2015-03-04 | 2024-05-13 | 머크 샤프 앤드 돔 코포레이션 | 암을 치료하기 위한 pd-1 길항제 및 vegfr/fgfr/ret 티로신 키나제 억제제의 조합 |
| SG11201710198YA (en) | 2015-06-16 | 2018-01-30 | Eisai R&D Man Co Ltd | Anticancer agent |
| ES2971448T3 (es) * | 2017-02-08 | 2024-06-05 | Eisai R&D Man Co Ltd | Composición farmacéutica para el tratamiento de tumores |
| WO2021086909A1 (en) | 2019-10-29 | 2021-05-06 | Eisai R&D Managment Co., Ltd. | Combination of a pd-1 antagonist, a vegfr/fgfr/ret tyrosine kinase inhibitor and a cbp/beta-catenin inhibitor for treating cancer |
| MX2024002060A (es) | 2021-09-08 | 2024-03-01 | Eisai R&D Man Co Ltd | Composicion farmaceutica para tratar tumores solidos. |
| AU2023246216A1 (en) | 2022-03-31 | 2024-09-19 | Eisai R&D Management Co., Ltd. | Pharmaceutical composition for treating tumors |
| CN115784934A (zh) * | 2022-11-22 | 2023-03-14 | 上海吉奉生物科技有限公司 | 一种酪氨酸衍生物的合成方法 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9714129D0 (en) | 1997-07-04 | 1997-09-10 | Pfizer Ltd | Azetidines |
| JP2003518123A (ja) | 1999-12-21 | 2003-06-03 | スージェン・インコーポレーテッド | ４−置換７−アザ−インドリン−２−オンおよびその蛋白質キナーゼ阻害剤としての使用 |
| CA2462922C (en) | 2001-10-12 | 2010-05-25 | Choongwae Pharma Corporation | Reverse-turn mimetics and method relating thereto |
| US8080657B2 (en) | 2001-10-12 | 2011-12-20 | Choongwae Pharma Corporation | Compounds of reverse turn mimetics and the use thereof |
| US7671054B1 (en) | 2001-10-12 | 2010-03-02 | Choongwae Pharma Corporation | Reverse-turn mimetics and method relating thereto |
| WO2006123517A1 (ja) * | 2005-04-26 | 2006-11-23 | Kissei Pharmaceutical Co., Ltd. | ヒドロキシノルエフェドリン誘導体塩酸塩の結晶多形 |
| US8455488B2 (en) | 2008-06-06 | 2013-06-04 | Prism Biolab Corporation | Alpha helix mimetics and methods relating thereto |
| UA103918C2 (en) | 2009-03-02 | 2013-12-10 | Айерем Элелси | N-(hetero)aryl, 2-(hetero)aryl-substituted acetamides for use as wnt signaling modulators |
| MX340424B (es) | 2009-04-15 | 2016-07-08 | Jw Pharmaceutical Corp | Compuestos novedosos de mimeticos de cambio inverso; metodo para fabricarlos y su uso. |
| CN103209982B (zh) | 2010-10-14 | 2016-03-16 | Jw制药公司 | 反转模拟物的化合物、其制造方法及其用途 |
| EP2678341A1 (en) | 2011-02-25 | 2014-01-01 | PRISM Pharma Co., Ltd. | Alpha helix mimetics and methods relating thereto |
| PH12017500997A1 (en) | 2012-04-04 | 2018-02-19 | Samumed Llc | Indazole inhibitors of the wnt signal pathway and therapeutic uses thereof |
| RS58432B1 (sr) | 2013-02-22 | 2019-04-30 | Samumed Llc | Gama-diketoni kao aktivatori wnt/beta-kateninakog signalnog puta |
| KR20160095171A (ko) * | 2013-12-25 | 2016-08-10 | 가부시키가이샤 프리즘 파마 | 피라지노[２,１－ｃ][１,２,４]트리아진 화합물의 결정 (２) |
| US9174998B2 (en) * | 2013-12-25 | 2015-11-03 | Eisai R&D Management Co., Ltd. | (6S,9aS)-N-benzyl-6-[(4-hydroxyphenyl)methyl]-4,7-dioxo-8-({6-[3-(piperazin-1-yl)azetidin-1-yl]pyridin-2-yl}methyl)-2-(prop-2-en-1-yl)-octahydro-1H-pyrazino[2,1-c][1,2,4]triazine-1-carboxamide compound |
-
2016
- 2016-06-21 CN CN201680030060.5A patent/CN107614504B/zh active Active
- 2016-06-21 JP JP2016572771A patent/JP6126319B1/ja active Active
- 2016-06-21 EP EP16814346.9A patent/EP3315499B1/en active Active
- 2016-06-21 WO PCT/JP2016/068381 patent/WO2016208576A1/ja active Application Filing
- 2016-06-21 CA CA2986999A patent/CA2986999C/en active Active
- 2016-06-21 RU RU2017141763A patent/RU2723551C2/ru active
- 2016-06-21 ES ES16814346T patent/ES2870013T3/es active Active
- 2016-06-21 AU AU2016284383A patent/AU2016284383B2/en active Active
- 2016-06-21 MX MX2017015257A patent/MX2017015257A/es unknown
- 2016-06-21 KR KR1020177033876A patent/KR102559211B1/ko active IP Right Grant
- 2016-06-21 US US15/577,858 patent/US10259817B2/en active Active
- 2016-06-21 SG SG11201709593VA patent/SG11201709593VA/en unknown
-
2017
- 2017-11-26 IL IL255901A patent/IL255901B/en active IP Right Grant
Also Published As
| Publication number | Publication date |
|---|---|
| RU2017141763A3 (zh) | 2019-08-23 |
| US20180141950A1 (en) | 2018-05-24 |
| IL255901A (en) | 2018-01-31 |
| EP3315499A4 (en) | 2018-12-19 |
| CA2986999A1 (en) | 2016-12-29 |
| AU2016284383A1 (en) | 2017-12-14 |
| EP3315499B1 (en) | 2021-04-07 |
| AU2016284383B2 (en) | 2020-08-20 |
| KR20180019083A (ko) | 2018-02-23 |
| RU2723551C2 (ru) | 2020-06-16 |
| WO2016208576A1 (ja) | 2016-12-29 |
| KR102559211B1 (ko) | 2023-07-25 |
| US10259817B2 (en) | 2019-04-16 |
| RU2017141763A (ru) | 2019-07-23 |
| MX2017015257A (es) | 2018-02-19 |
| IL255901B (en) | 2020-07-30 |
| BR112017025519A2 (pt) | 2018-08-07 |
| EP3315499A1 (en) | 2018-05-02 |
| CA2986999C (en) | 2023-08-08 |
| ES2870013T3 (es) | 2021-10-26 |
| CN107614504B (zh) | 2019-12-24 |
| JPWO2016208576A1 (ja) | 2017-06-29 |
| JP6126319B1 (ja) | 2017-05-10 |
| CN107614504A (zh) | 2018-01-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL245961A0 (en) | Compound (6s,9as)-n-benzyl-6-[(4-hydroxyphenyl)methyl]-4,7-dioxo-8-({6-[3-(piperazin-1-yl)azetidin-1-yl] Pyridin-2-yl}methyl)-2-(prop-2-en-1-yl)-octahydro-1h-pyrazino[2,1-c][1,2,4]triazine-1-carboxamide | |
| SG11201709593VA (en) | CRYSTAL OF (6S,9aS)-N-BENZYL-6-[(4-HYDROXYPHENYL)METHYL]- 4,7-DIOXO-8-({6-[3-(PIPERAZIN-1-YL)AZETIDIN-1-YL]PYRIDIN- 2-YL}METHYL)-2-(PROP-2-EN-1-YL)-OCTAHYDRO-1H-PYRAZINO[2,1-c][1,2,4]TRIAZINE-1-CARBOXAMIDE COMPOUND | |
| EP3331880A4 (en) | N- (PYRIDIN-2-YL) -4- (THIAZOL-5-YL) PYRIMIDIN-2-AMINE DERIVATIVES AS THERAPEUTIC COMPOUNDS | |
| HK1213569A1 (zh) | 用於治療病毒性感染的 -氨基嘧啶衍生物 | |
| EP3229812A4 (en) | Synthetic composition for treating metabolic disorders | |
| SI3805233T1 (sl) | (r)in (s) enantiomera n-(5-(3-hidroksipirolidin-1-il)-2-morfolinooksazolo(4,5-b)piridin-6-il) -2-(2-metilpiridin-4-il)oksazol-karboksamid kot inhibitorji irak4 za zdravljenje raka | |
| HRP20181698T1 (hr) | 2-amino-6-(difluormetil)-5,5-difluor-6-fenil-3,4,5,6-tetrahidropiridini kao inhibitori bace1 | |
| PL2900637T3 (pl) | Pirymidyna podstawiona tiazolem lub imidazolem, amidowe pochodne pirazyny i pirydyny i powiązane związki takie jak inhibitory abl1, abl2 i bcr-abl1 do leczenia nowotworu, specyficznych infekcji wirusowych i specyficznych zaburzeń cns | |
| PL2987791T3 (pl) | Pochodna kwasu 3-(4-benzyloksy(fenylo)heks-4-ynowego odpowiednia do zapobiegania i leczenia chorób metabolicznych | |
| HUE056922T2 (hu) | 2-szubsztituált amino-naft[1,2-D]imidazol-5-on vegyületek vagy azok gyógyszerészetileg elfogadható sói | |
| EP3373931A4 (en) | HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF DISEASES | |
| EP3198635A4 (en) | Multi-chip self adjusting cooling solution | |
| EP3200792A4 (en) | Poly (adp-ribose) polymerase 1 inhibitors structurally unrelated to nad | |
| EP3475299A4 (en) | COMPOUNDS USEFUL FOR TREATING METABOLIC DISORDERS | |
| IL243637B (en) | PPAR-sparing compounds for the treatment of metabolic diseases | |
| TH1601003377A (th) | สารประกอบ (6S,9aS)-N-เบนซิล-6-[(4-ไฮดรอกซีฟีนิล)เมทิล]-4,7-ไดออกโซ-8-({6-[3-(พิเพอราซิน-1-อิล)อะเซทิดิน-1-อิล]ไพริดิน-2-อิล}เมทิล)-2-(พรอพ-2-เอน-1-อิล)-ออคตะไฮโดร-1H-ไพราซิโน[2,1-c][1,2,4]ไตรอะซีน-1-คาร์บอกซาไมด์ |